Bevacizumab in ovarian cancer: A critical review of phase III studies
- PMID:27852039
- PMCID: PMC5355353
- DOI: 10.18632/oncotarget.13310
Bevacizumab in ovarian cancer: A critical review of phase III studies
Abstract
Bevacizumab (BV) is a humanized monoclonal antibody targeting vascular endothelial growth factor and it is the first molecular-targeted agent to be used for the treatment of ovarian cancer (OC). Randomized Phase III trials evaluated the combination of BV plus standard chemotherapy for first-line treatment of advanced OC and for platinum-sensitive and platinum-resistant recurrent OC. These trials reported a statistically significant improvement in progression-free survival but not in overall survival. Furthermore, BV effectively improved the quality of life with regard to abdominal symptoms in recurrent OC patients. Bevacizumab is associated with adverse events such as hypertension, bleeding, thromboembolism, proteinuria, delayed wound healing, and gastrointestinal events. However, most of these events can be adequately managed. This review describes the latest evidence for BV treatment of OC and selection of patients for personalized treatment.
Keywords: anti-angiogenic therapy; bevacizumab; biological therapy; chemotherapy; ovarian cancer.
Conflict of interest statement
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents, received or pending, or royalties.
Similar articles
- Critical appraisal of bevacizumab in the treatment of ovarian cancer.Yoshida H, Yabuno A, Fujiwara K.Yoshida H, et al.Drug Des Devel Ther. 2015 Apr 28;9:2351-8. doi: 10.2147/DDDT.S83275. eCollection 2015.Drug Des Devel Ther. 2015.PMID:25960638Free PMC article.Review.
- Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.Wu YS, Shui L, Shen D, Chen X.Wu YS, et al.Oncotarget. 2017 Feb 7;8(6):10703-10713. doi: 10.18632/oncotarget.12926.Oncotarget. 2017.PMID:27793044Free PMC article.Review.
- Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I.Pujade-Lauraine E, et al.J Clin Oncol. 2014 May 1;32(13):1302-8. doi: 10.1200/JCO.2013.51.4489. Epub 2014 Mar 17.J Clin Oncol. 2014.PMID:24637997Clinical Trial.
- Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E; AURELIA Investigators.Sorio R, et al.Gynecol Oncol. 2017 Jan;144(1):65-71. doi: 10.1016/j.ygyno.2016.11.006. Epub 2016 Nov 18.Gynecol Oncol. 2017.PMID:27871723Clinical Trial.
- Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review.Aravantinos G, Pectasides D.Aravantinos G, et al.J Ovarian Res. 2014 May 19;7:57. doi: 10.1186/1757-2215-7-57. eCollection 2014.J Ovarian Res. 2014.PMID:24864163Free PMC article.Review.
Cited by
- PARP Inhibitors in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials.Wang Y, Ren F, Song Z, Wang X, Zhang C, Ouyang L.Wang Y, et al.Front Oncol. 2020 Aug 4;10:1204. doi: 10.3389/fonc.2020.01204. eCollection 2020.Front Oncol. 2020.PMID:32850351Free PMC article.
- Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment.Lee JM, Annunziata CM, Hays JL, Cao L, Choyke P, Yu M, An D, Turkbey IB, Minasian LM, Steinberg SM, Chen H, Wright J, Kohn EC.Lee JM, et al.Gynecol Oncol. 2020 Oct;159(1):88-94. doi: 10.1016/j.ygyno.2020.07.031. Epub 2020 Aug 1.Gynecol Oncol. 2020.PMID:32747013Free PMC article.Clinical Trial.
- What is new about ovarian malignancies?Grabska K, Pilarska I, Fudalej MM, Deptała A, Badowska-Kozakiewicz A.Grabska K, et al.Contemp Oncol (Pozn). 2021;25(4):225-231. doi: 10.5114/wo.2021.112037. Epub 2021 Dec 29.Contemp Oncol (Pozn). 2021.PMID:35079229Free PMC article.Review.
- The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes.James NE, Emerson JB, Borgstadt AD, Beffa L, Oliver MT, Hovanesian V, Urh A, Singh RK, Rowswell-Turner R, DiSilvestro PA, Ou J, Moore RG, Ribeiro JR.James NE, et al.Sci Rep. 2020 May 22;10(1):8558. doi: 10.1038/s41598-020-65353-x.Sci Rep. 2020.PMID:32444701Free PMC article.
- Immunological configuration of ovarian carcinoma: features and impact on disease outcome.Fucikova J, Coosemans A, Orsulic S, Cibula D, Vergote I, Galluzzi L, Spisek R.Fucikova J, et al.J Immunother Cancer. 2021 Oct;9(10):e002873. doi: 10.1136/jitc-2021-002873.J Immunother Cancer. 2021.PMID:34645669Free PMC article.Review.
References
- De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G, Nennecke A, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol. 2014;15:23–34. - PubMed
- Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, de Swart CA, Hirsch FR, Lund B, van Houwelingen HC. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 2000;18:3084–3092. - PubMed
- Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R, Gynecologic Oncology Group Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2003;21:3194–3200. - PubMed
- Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27:1419–1425. - PMC - PubMed
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical